HTA bodies

MASH, a serious fatty liver disease, is becoming a cardiometabolic condition

ENDO 2026 reveals the GLP-1 revolution’s real challenge: delivery

MRD Testing Moves From Prognosis Toward Treatment Action

Precision cardiology is becoming the new oncology. Policy and reimbursement must catch up

ALS Survival Data Return to the Evidence Debate

Sanofi’s Tzield moves type 1 diabetes into disease modification, but access may decide who benefits

WHO is preparing to ration the obesity drug revolution before it becomes another access disaster

ALS Immunotherapy Moves Into the Extension Phase

Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
